<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38132646</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2308-3425</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Journal of cardiovascular development and disease</Title><ISOAbbreviation>J Cardiovasc Dev Dis</ISOAbbreviation></Journal><ArticleTitle>SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">478</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcdd10120478</ELocationID><Abstract><AbstractText>The coronavirus disease (COVID)-19 has turned into a pandemic causing a global public health crisis. While acute COVID-19 mainly affects the respiratory system and can cause acute respiratory distress syndrome, an association with persistent inflammatory stress affecting different organ systems has been elucidated in long COVID syndrome (LCS). Increased severity and mortality rates have been reported due to cardiophysiological and metabolic systemic disorders as well as multiorgan failure in COVID-19, additionally accompanied by chronic dyspnea and fatigue in LCS. Hence, novel therapies have been tested to improve the outcomes of LCS of which one potential candidate might be sodium-glucose cotransporter 2 (SGLT2) inhibitors. The aim of this narrative review was to discuss rationales for investigating SGLT2 inhibitor therapy in people suffering from LCS. In this regard, we discuss their potential positive effects-next to the well described "cardio-renal-metabolic" conditions-with a focus on potential anti-inflammatory and beneficial systemic effects in LCS. However, potential beneficial as well as potential disadvantageous effects of SGLT2 inhibitors on the prevalence and long-term outcomes of COVID-19 will need to be established in ongoing research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmermann</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Exercise Physiology and Metabolism, BaySpo-Bayreuth Center of Sport Science, University of Bayreuth, 95440 Bayreuth, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Center of Sportsmedicine Bamberg, Klinikum Bamberg, 96049 Bamberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Klinikum Bamberg, 96049 Bamberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sourij</LastName><ForeName>Harald</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3510-9594</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Metabolic Medicine Research Group, Division of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aberer</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9947-1413</Identifier><AffiliationInfo><Affiliation>Interdisciplinary Metabolic Medicine Research Group, Division of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rilstone</LastName><ForeName>Sian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Exercise Physiology and Metabolism, BaySpo-Bayreuth Center of Sport Science, University of Bayreuth, 95440 Bayreuth, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schierbauer</LastName><ForeName>Janis</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7761-9261</Identifier><AffiliationInfo><Affiliation>Division of Exercise Physiology and Metabolism, BaySpo-Bayreuth Center of Sport Science, University of Bayreuth, 95440 Bayreuth, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moser</LastName><ForeName>Othmar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Exercise Physiology and Metabolism, BaySpo-Bayreuth Center of Sport Science, University of Bayreuth, 95440 Bayreuth, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Metabolic Medicine Research Group, Division of Endocrinology and Diabetology, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Cardiovasc Dev Dis</MedlineTA><NlmUniqueID>101651414</NlmUniqueID><ISSNLinking>2308-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SGLT2 inhibitors</Keyword><Keyword MajorTopicYN="N">cardiovascular disorders</Keyword><Keyword MajorTopicYN="N">coronavirus disease (COVID)-19</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">long COVID and cardiovascular sequelae</Keyword><Keyword MajorTopicYN="N">long COVID syndrome</Keyword><Keyword MajorTopicYN="N">sodium&#x2013;glucose cotransporter 2 inhibitors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38132646</ArticleId><ArticleId IdType="pmc">PMC10744331</ArticleId><ArticleId IdType="doi">10.3390/jcdd10120478</ArticleId><ArticleId IdType="pii">jcdd10120478</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chee Y.J., Tan S.K., Yeoh E. Dissecting the Interaction between COVID-19 and Diabetes Mellitus. J. Diabetes Investig. 2020;11:1104&#x2013;1114. doi: 10.1111/jdi.13326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13326</ArticleId><ArticleId IdType="pmc">PMC7323255</ArticleId><ArticleId IdType="pubmed">32558211</ArticleId></ArticleIdList></Reference><Reference><Citation> [(accessed on 5 October 2023)].  Available online:  https://Covid19.Who.Int.</Citation></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;&#x2014;A Hypothesis for Understanding the Biological Basis and Pharmacological Treatment Strategy. Pharmacol. Res. Perspect. 2022;10:e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91:157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P., Aberer F., Braun M., Sourij H., Moser O. The Arrhythmogenic Face of COVID-19: Brugada ECG Pattern in SARS-CoV-2 Infection. J. Cardiovasc. Dev. Dis. 2022;9:96. doi: 10.3390/jcdd9040096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd9040096</ArticleId><ArticleId IdType="pmc">PMC9027624</ArticleId><ArticleId IdType="pubmed">35448072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman S., Montero M.T.V., Rowe K., Kirton R., Kunik F. Epidemiology, Pathogenesis, Clinical Presentations, Diagnosis and Treatment of COVID-19: A Review of Current Evidence. Expert Rev. Clin. Pharmacol. 2021;14:601&#x2013;621. doi: 10.1080/17512433.2021.1902303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2021.1902303</ArticleId><ArticleId IdType="pmc">PMC8095162</ArticleId><ArticleId IdType="pubmed">33705239</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner M.J., Bruno K.A., Klassen S.A., Kunze K.L., Johnson P.W., Lesser E.R., Wiggins C.C., Senefeld J.W., Klompas A.M., Hodge D.O., et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin. Proc. 2020;95:1888&#x2013;1897. doi: 10.1016/j.mayocp.2020.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.06.028</ArticleId><ArticleId IdType="pmc">PMC7368917</ArticleId><ArticleId IdType="pubmed">32861333</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallard E., Lescure F.-X., Yazdanpanah Y., Mentre F., Peiffer-Smadja N. Type 1 Interferons as a Potential Treatment against COVID-19. Antivir. Res. 2020;178:104791. doi: 10.1016/j.antiviral.2020.104791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104791</ArticleId><ArticleId IdType="pmc">PMC7138382</ArticleId><ArticleId IdType="pubmed">32275914</ArticleId></ArticleIdList></Reference><Reference><Citation>Effect of Hydroxychloroquine in Hospitalized Patients with COVID19. N. Engl. J. Med. 2020;383:2030&#x2013;2040. doi: 10.1056/NEJMoa2022926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022926</ArticleId><ArticleId IdType="pmc">PMC7556338</ArticleId><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Z., Wang Y., Colunga-Lozano L.E., Prasad M., Tangamornsuksan W., Rochwerg B., Yao L., Motaghi S., Couban R.J., Ghadimi M., et al. Efficacy and Safety of Corticosteroids in COVID-19 Based on Evidence for COVID-19, Other Coronavirus Infections, Influenza, Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. CMAJ. 2020;192:E756&#x2013;E767. doi: 10.1503/cmaj.200645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.200645</ArticleId><ArticleId IdType="pmc">PMC7828900</ArticleId><ArticleId IdType="pubmed">32409522</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Pan H., Peto R., Henao-Restrepo A.-M., Preziosi M.-P., Sathiyamoorthy V., Abdool Karim Q., Alejandria M.M., Hern&#xe1;ndez Garc&#xed;a C., Kieny M.-P., et al. Repurposed Antiviral Drugs for COVID-19&#x2014;Interim WHO Solidarity Trial Results. N. Engl. J. Med. 2021;384:497&#x2013;511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major Findings, Mechanisms and Recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M., Iwasaki A. The Neurobiology of Long COVID. Neuron. 2022;110:3484&#x2013;3496. doi: 10.1016/j.neuron.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Bluemke D.A., L&#xfc;scher T.F., Neubauer S. Long COVID: Post-Acute Sequelae of COVID-19 with a Cardiovascular Focus. Eur. Heart J. 2022;43:1157&#x2013;1172. doi: 10.1093/eurheartj/ehac031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac031</ArticleId><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Understanding Long COVID: A Modern Medical Challenge. Lancet. 2021;398:725. doi: 10.1016/S0140-6736(21)01900-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01900-0</ArticleId><ArticleId IdType="pmc">PMC8389978</ArticleId><ArticleId IdType="pubmed">34454656</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., Debski M., Naing T.K.P., Garg P., Clark A., Ntatsaki E., Vassiliou V.S. Risk Factors Associated With Post&#x2212;COVID-19 Condition. JAMA Intern. Med. 2023;183:566. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y., Jiao B., Qu L., Yang D., Liu R. The Development of COVID-19 Treatment. Front. Immunol. 2023;14:1125246. doi: 10.3389/fimmu.2023.1125246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1125246</ArticleId><ArticleId IdType="pmc">PMC9909293</ArticleId><ArticleId IdType="pubmed">36776881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Rizky L., Stefanovic N., Tate M., Ritchie R.H., Ward K.W., de Haan J.B. The Nuclear Factor (Erythroid-Derived 2)-like 2 (Nrf2) Activator Dh404 Protects against Diabetes-Induced Endothelial Dysfunction. Cardiovasc. Diabetol. 2017;16:33. doi: 10.1186/s12933-017-0513-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-017-0513-y</ArticleId><ArticleId IdType="pmc">PMC5335831</ArticleId><ArticleId IdType="pubmed">28253885</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachou M., Siamidi A., Dedeloudi A., Konstantinidou S., Papanastasiou I. Pineal Hormone Melatonin as an Adjuvant Treatment for COVID-19 (Review) Int. J. Mol. Med. 2021;47:47. doi: 10.3892/ijmm.2021.4880.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2021.4880</ArticleId><ArticleId IdType="pmc">PMC7891824</ArticleId><ArticleId IdType="pubmed">33576451</ArticleId></ArticleIdList></Reference><Reference><Citation>Melhuish Beaupre L.M., Brown G.M., Gon&#xe7;alves V.F., Kennedy J.L. Melatonin&#x2019;s Neuroprotective Role in Mitochondria and Its Potential as a Biomarker in Aging, Cognition and Psychiatric Disorders. Transl. Psychiatry. 2021;11:339. doi: 10.1038/s41398-021-01464-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-021-01464-x</ArticleId><ArticleId IdType="pmc">PMC8172874</ArticleId><ArticleId IdType="pubmed">34078880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriend J., Reiter R.J. The Keap1-Nrf2-Antioxidant Response Element Pathway: A Review of Its Regulation by Melatonin and the Proteasome. Mol. Cell Endocrinol. 2015;401:213&#x2013;220. doi: 10.1016/j.mce.2014.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2014.12.013</ArticleId><ArticleId IdType="pubmed">25528518</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M., Takahashi Y., Tabuchi T., Minami Y., Tamada M., Takahashi K., Itoh T., Morino Y., Nakamura M. Cellular and Molecular Mechanisms of Statins: An Update on Pleiotropic Effects. Clin. Sci. 2015;129:93&#x2013;105. doi: 10.1042/CS20150027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20150027</ArticleId><ArticleId IdType="pubmed">25927679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs J., de Boer R.A., Lindenfeld J., Bozkurt B. The Year in Cardiovascular Medicine 2021: Heart Failure and Cardiomyopathies. Eur. Heart J. 2022;43:367&#x2013;376. doi: 10.1093/eurheartj/ehab887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab887</ArticleId><ArticleId IdType="pmc">PMC9383181</ArticleId><ArticleId IdType="pubmed">34974611</ArticleId></ArticleIdList></Reference><Reference><Citation>Frampton J.E. Empagliflozin: A Review in Type 2 Diabetes. Drugs. 2018;78:1037&#x2013;1048. doi: 10.1007/s40265-018-0937-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-018-0937-z</ArticleId><ArticleId IdType="pubmed">29946963</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielka W., Przezak A., Pawlik A. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection. Int. J. Mol. Sci. 2021;22:7605. doi: 10.3390/ijms22147605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22147605</ArticleId><ArticleId IdType="pmc">PMC8306903</ArticleId><ArticleId IdType="pubmed">34299225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zannad F., Ferreira J.P., Pocock S.J., Anker S.D., Butler J., Filippatos G., Brueckmann M., Ofstad A.P., Pfarr E., Jamal W., et al. SGLT2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials. Lancet. 2020;396:819&#x2013;829. doi: 10.1016/S0140-6736(20)31824-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31824-9</ArticleId><ArticleId IdType="pubmed">32877652</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon S.D., McMurray J.J.V., Claggett B., de Boer R.A., DeMets D., Hernandez A.F., Inzucchi S.E., Kosiborod M.N., Lam C.S.P., Martinez F., et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J. Med. 2022;387:1089&#x2013;1098. doi: 10.1056/NEJMoa2206286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2206286</ArticleId><ArticleId IdType="pubmed">36027570</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatore T., Galiero R., Caturano A., Rinaldi L., Di Martino A., Albanese G., Di Salvo J., Epifani R., Marfella R., Docimo G., et al. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int. J. Mol. Sci. 2022;23:3651. doi: 10.3390/ijms23073651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23073651</ArticleId><ArticleId IdType="pmc">PMC8998569</ArticleId><ArticleId IdType="pubmed">35409011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mende C.W. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv. Ther. 2022;39:148&#x2013;164. doi: 10.1007/s12325-021-01994-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01994-2</ArticleId><ArticleId IdType="pmc">PMC8799531</ArticleId><ArticleId IdType="pubmed">34846711</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiki N., G&#xf3;mez-Huelgas R., Mikhailidis D.P., P&#xe9;rez-Mart&#xed;nez P. Narrative Review on Clinical Considerations for Patients with Diabetes and COVID-19: More Questions than Answers. Int. J. Clin. Pract. 2021;75:e14833. doi: 10.1111/ijcp.14833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14833</ArticleId><ArticleId IdType="pmc">PMC8646329</ArticleId><ArticleId IdType="pubmed">34510676</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M., Rayner C., Delaney B. Fresh Evidence of the Scale and Scope of Long COVID. BMJ. 2021;373:n853. doi: 10.1136/bmj.n853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n853</ArticleId><ArticleId IdType="pubmed">33795224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-Acute COVID-19 Syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE) COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. National Institute for Health and Care Excellence (NICE); London, UK: 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabria M., Garc&#xed;a-S&#xe1;nchez C., Grunden N., Pons C., Arroyo J.A., G&#xf3;mez-Anson B., Est&#xe9;vez Garc&#xed;a M.D.C., Belv&#xed;s R., Moroll&#xf3;n N., Vera Igual J., et al. Post-COVID-19 Fatigue: The Contribution of Cognitive and Neuropsychiatric Symptoms. J. Neurol. 2022;269:3990&#x2013;3999. doi: 10.1007/s00415-022-11141-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11141-8</ArticleId><ArticleId IdType="pmc">PMC9055007</ArticleId><ArticleId IdType="pubmed">35488918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukkahatai N., Rodney T., Ling C., Daniel B., Han H.-R. Long COVID in the Context of Social Determinants of Health. Front. Public. Health. 2023;11:1098443. doi: 10.3389/fpubh.2023.1098443.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1098443</ArticleId><ArticleId IdType="pmc">PMC10088562</ArticleId><ArticleId IdType="pubmed">37056649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. Long COVID: How to Define It and How to Manage It. BMJ. 2020;370:m3489. doi: 10.1136/bmj.m3489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3489</ArticleId><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund L.C., Hallas J., Nielsen H., Koch A., Mogensen S.H., Brun N.C., Christiansen C.F., Thomsen R.W., Potteg&#xe5;rd A. Post-Acute Effects of SARS-CoV-2 Infection in Individuals Not Requiring Hospital Admission: A Danish Population-Based Cohort Study. Lancet Infect. Dis. 2021;21:1373&#x2013;1382. doi: 10.1016/S1473-3099(21)00211-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A., M&#xfc;ller B., Merle U. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin. Infect. Dis. 2022;74:1191&#x2013;1198. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., Horn C., Vanshylla K., Di Cristanziano V., Osebold L., et al. Post-COVID Syndrome in Non-Hospitalised Patients with COVID-19: A Longitudinal Prospective Cohort Study. Lancet Reg. Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., Mitchell R.E., Niedzwiedz C.L., Yang T.C., Huggins C.F., Kwong A.S.F., Silverwood R.J., Di Gessa G., et al. Long COVID Burden and Risk Factors in 10 UK Longitudinal Studies and Electronic Health Records. Nat. Commun. 2022;13:3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M., Elliott J., Chadeau-Hyam M., Riley S., Darzi A., Cooke G., Ward H., Elliott P. Persistent COVID-19 Symptoms in a Community Study of 606,434 People in England. Nat. Commun. 2022;13:1957. doi: 10.1038/s41467-022-29521-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and Predictors of Long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of Post-Acute COVID-19 in Primary Care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Perego E., Callard F., Stras L., Melville-Johannesson B., Pope R., Alwan N. Why We Need to Keep Using the Patient Made Term &#x201c;Long COVID&#x201d;. University of Southampton Institutional Repository; Southampton, UK: 2020.</Citation></Reference><Reference><Citation>Dong E., Du H., Gardner L. An Interactive Web-Based Dashboard to Track COVID-19 in Real Time. Lancet Infect. Dis. 2020;20:533&#x2013;534. doi: 10.1016/S1473-3099(20)30120-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30120-1</ArticleId><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard L. SARS-CoV-2 Related Microvascular Damage and Symptoms during and after COVID-19: Consequences of Capillary Transit-Time Changes, Tissue Hypoxia and Inflammation. Physiol. Rep. 2021;9:e14726. doi: 10.14814/phy2.14726.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14726</ArticleId><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro L., Zaccone V., Falsetti L., Ruggieri V., Danese M., Miro C., Di Giorgio A., Nesci A., D&#x2019;Alessandro A., Moroncini G., et al. Role of Endothelium in Cardiovascular Sequelae of Long COVID. Biomedicines. 2023;11:2239. doi: 10.3390/biomedicines11082239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11082239</ArticleId><ArticleId IdType="pmc">PMC10452509</ArticleId><ArticleId IdType="pubmed">37626735</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro L., Falsetti L., Zaccone V., Nesci A., Tosato M., Giupponi B., Savastano M.C., Moroncini G., Gasbarrini A., Landi F., et al. Impaired Endothelial Function in Convalescent Phase of COVID-19: A 3 Month Follow Up Observational Prospective Study. J. Clin. Med. 2022;11:1774. doi: 10.3390/jcm11071774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11071774</ArticleId><ArticleId IdType="pmc">PMC8999944</ArticleId><ArticleId IdType="pubmed">35407382</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso C., Leone O., Rizzo S., De Gaspari M., van der Wal A.C., Aubry M.-C., Bois M.C., Lin P.T., Maleszewski J.J., Stone J.R. Pathological Features of COVID-19-Associated Myocardial Injury: A Multicentre Cardiovascular Pathology Study. Eur. Heart J. 2020;41:3827&#x2013;3835. doi: 10.1093/eurheartj/ehaa664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa664</ArticleId><ArticleId IdType="pmc">PMC7543528</ArticleId><ArticleId IdType="pubmed">32968776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner D., Fitzek A., Br&#xe4;uninger H., Aleshcheva G., Edler C., Meissner K., Scherschel K., Kirchhof P., Escher F., Schultheiss H.-P., et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020;5:1281&#x2013;1285. doi: 10.1001/jamacardio.2020.3551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3551</ArticleId><ArticleId IdType="pmc">PMC7385672</ArticleId><ArticleId IdType="pubmed">32730555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bois M.C., Boire N.A., Layman A.J., Aubry M.-C., Alexander M.P., Roden A.C., Hagen C.E., Quinton R.A., Larsen C., Erben Y., et al. COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart. Circulation. 2021;143:230&#x2013;243. doi: 10.1161/CIRCULATIONAHA.120.050754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050754</ArticleId><ArticleId IdType="pmc">PMC7805556</ArticleId><ArticleId IdType="pubmed">33197204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Xie X., Tu Z., Fu J., Xu D., Zhou Y. The Signal Pathways and Treatment of Cytokine Storm in COVID-19. Signal Transduct. Target. Ther. 2021;6:255. doi: 10.1038/s41392-021-00679-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z., Li S., Song X. Cytokine Storm with Rapidly Elevated Interleukin-6 Indicates Sudden Death in Patients with Critical COVID-19. Cytokine Growth Factor. Rev. 2021;58:30&#x2013;31. doi: 10.1016/j.cytogfr.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.08.001</ArticleId><ArticleId IdType="pmc">PMC7445135</ArticleId><ArticleId IdType="pubmed">32873506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A. Post-COVID Syndrome in Individuals Admitted to Hospital with COVID-19: Retrospective Cohort Study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann V.O., Carerj M.L., Wieters I., Fahim M., Arendt C., Hoffmann J., Shchendrygina A., Escher F., Vasa-Nicotera M., Zeiher A.M., et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265&#x2013;1273. doi: 10.1001/jamacardio.2020.3557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassar M.P., Tunnicliffe E.M., Petousi N., Lewandowski A.J., Xie C., Mahmod M., Samat A.H.A., Evans R.A., Brightling C.E., Ho L.-P., et al. Symptom Persistence Despite Improvement in Cardiopulmonary Health&#x2014;Insights from Longitudinal CMR, CPET and Lung Function Testing Post-COVID-19. EClinicalMedicine. 2021;41:101159. doi: 10.1016/j.eclinm.2021.101159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101159</ArticleId><ArticleId IdType="pmc">PMC8527025</ArticleId><ArticleId IdType="pubmed">34693230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr A., Dannerbeck L., Lange T.J., Pfeifer M., Blaas S., Salzberger B., Hitzenbichler F., Koch M. Cardiopulmonary Exercise Pattern in Patients with Persistent Dyspnoea after Recovery from COVID-19. Multidiscip. Respir. Med. 2021;16:732. doi: 10.4081/mrm.2021.732.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/mrm.2021.732</ArticleId><ArticleId IdType="pmc">PMC7893311</ArticleId><ArticleId IdType="pubmed">33623700</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson M., St&#xe5;hlberg M., Runold M., Nygren-Bonnier M., Nilsson J., Olshansky B., Bruchfeld J., Fedorowski A. Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience. JACC Case Rep. 2021;3:573&#x2013;580. doi: 10.1016/j.jaccas.2021.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2021.01.009</ArticleId><ArticleId IdType="pmc">PMC7946344</ArticleId><ArticleId IdType="pubmed">33723532</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M., Dirksen A., Taraborrelli P., Torocastro M., Panagopoulos D., Sutton R., Lim P.B. Autonomic Dysfunction in &#x201c;Long COVID&#x201d;: Rationale, Physiology and Management Strategies. Clin. Med. 2021;21:e63&#x2013;e67. doi: 10.7861/clinmed.2020-0896.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S., Whitelaw S. Postural Orthostatic Tachycardia Syndrome (POTS) and Other Autonomic Disorders after COVID-19 Infection: A Case Series of 20 Patients. Immunol. Res. 2021;69:205&#x2013;211. doi: 10.1007/s12026-021-09185-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-021-09185-5</ArticleId><ArticleId IdType="pmc">PMC8009458</ArticleId><ArticleId IdType="pubmed">33786700</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., McAuley H., Harrison E.M., Shikotra A., Singapuri A., Sereno M., Elneima O., Docherty A.B., Lone N.I., Leavy O.C., et al. Physical, Cognitive, and Mental Health Impacts of COVID-19 after Hospitalisation (PHOSP-COVID): A UK Multicentre, Prospective Cohort Study. Lancet Respir. Med. 2021;9:1275&#x2013;1287. doi: 10.1016/S2213-2600(21)00383-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding J.L., Oviedo S.A., Ali M.K., Ofotokun I., Gander J.C., Patel S.A., Magliano D.J., Patzer R.E. The Bidirectional Association between Diabetes and Long-COVID-19&#x2014;A Systematic Review. Diabetes Res. Clin. Pract. 2023;195:110202. doi: 10.1016/j.diabres.2022.110202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2022.110202</ArticleId><ArticleId IdType="pmc">PMC9727969</ArticleId><ArticleId IdType="pubmed">36496030</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Al-Aly Z. Risks and Burdens of Incident Diabetes in Long COVID: A Cohort Study. Lancet Diabetes Endocrinol. 2022;10:311&#x2013;321. doi: 10.1016/S2213-8587(22)00044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Buse J.B., Liebovitz D.M., Nicklas J.M., Puskarich M.A., Cohen K., Belani H.K., Anderson B.J., Huling J.D., Tignanelli C.J., et al. Outpatient Treatment of COVID-19 and Incidence of Post-COVID-19 Condition over 10 Months (COVID-OUT): A Multicentre, Randomised, Quadruple-Blind, Parallel-Group, Phase 3 Trial. Lancet Infect. Dis. 2023;23:1119&#x2013;1129. doi: 10.1016/S1473-3099(23)00299-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen A.J. SGLT2 Inhibition during the COVID-19 Epidemic: Friend or Foe? Diabetes Metab. 2020;46:343&#x2013;344. doi: 10.1016/j.diabet.2020.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2020.06.003</ArticleId><ArticleId IdType="pmc">PMC7836403</ArticleId><ArticleId IdType="pubmed">32562762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet F., Scheen A.J. Effects of SGLT2 Inhibitors on Systemic and Tissue Low-Grade Inflammation: The Potential Contribution to Diabetes Complications and Cardiovascular Disease. Diabetes Metab. 2018;44:457&#x2013;464. doi: 10.1016/j.diabet.2018.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2018.09.005</ArticleId><ArticleId IdType="pubmed">30266577</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshnbari A., Idris I. Can Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor Reduce the Risk of Adverse Complications Due to COVID-19?&#x2014;Targeting Hyperinflammation. Curr. Med. Res. Opin. 2022;38:357&#x2013;364. doi: 10.1080/03007995.2022.2027141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2027141</ArticleId><ArticleId IdType="pmc">PMC8787835</ArticleId><ArticleId IdType="pubmed">35057687</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedikt M., Mangge H., Aziz F., Curcic P., Pailer S., Herrmann M., Kolesnik E., Tripolt N.J., Pferschy P.N., Wallner M., et al. Impact of the SGLT2-Inhibitor Empagliflozin on Inflammatory Biomarkers after Acute Myocardial Infarction&#x2014;A Post-Hoc Analysis of the EMMY Trial. Cardiovasc. Diabetol. 2023;22:166. doi: 10.1186/s12933-023-01904-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01904-6</ArticleId><ArticleId IdType="pmc">PMC10324245</ArticleId><ArticleId IdType="pubmed">37407956</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Ota T. Emerging Roles of SGLT2 Inhibitors in Obesity and Insulin Resistance: Focus on Fat Browning and Macrophage Polarization. Adipocyte. 2018;7:121&#x2013;128. doi: 10.1080/21623945.2017.1413516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21623945.2017.1413516</ArticleId><ArticleId IdType="pmc">PMC6152529</ArticleId><ArticleId IdType="pubmed">29376471</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen A.J., Marre M., Thivolet C. Prognostic Factors in Patients with Diabetes Hospitalized for COVID-19: Findings from the CORONADO Study and Other Recent Reports. Diabetes Metab. 2020;46:265&#x2013;271. doi: 10.1016/j.diabet.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7241378</ArticleId><ArticleId IdType="pubmed">32447101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.M., Caplice N.M. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019? Obesity. 2020;28:1191&#x2013;1194. doi: 10.1002/oby.22843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22843</ArticleId><ArticleId IdType="pmc">PMC7264526</ArticleId><ArticleId IdType="pubmed">32314868</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni S., Dyck J.R.B. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients. Can. J. Cardiol. 2020;36:1691.e3. doi: 10.1016/j.cjca.2020.07.230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2020.07.230</ArticleId><ArticleId IdType="pmc">PMC7378495</ArticleId><ArticleId IdType="pubmed">32717278</ArticleId></ArticleIdList></Reference><Reference><Citation>Koufakis T., Pavlidis A.N., Metallidis S., Kotsa K. Sodium-Glucose Co-Transporter 2 Inhibitors in COVID-19: Meeting at the Crossroads between Heart, Diabetes and Infectious Diseases. Int. J. Clin. Pharm. 2021;43:764&#x2013;767. doi: 10.1007/s11096-021-01256-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-021-01256-9</ArticleId><ArticleId IdType="pmc">PMC7942520</ArticleId><ArticleId IdType="pubmed">33751323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cure E., Cumhur Cure M. Can Dapagliflozin Have a Protective Effect against COVID-19 Infection? A Hypothesis. Diabetes Metab. Syndr. 2020;14:405&#x2013;406. doi: 10.1016/j.dsx.2020.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.04.024</ArticleId><ArticleId IdType="pmc">PMC7195078</ArticleId><ArticleId IdType="pubmed">32335366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossello X., Caimari F. Dapagliflozin in Patients with COVID-19: Truth or Dare. Lancet Diabetes Endocrinol. 2021;9:550&#x2013;551. doi: 10.1016/S2213-8587(21)00206-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00206-0</ArticleId><ArticleId IdType="pmc">PMC8294806</ArticleId><ArticleId IdType="pubmed">34302746</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy M.W. Novel Strategies for the Treatment of COVID-19. Drugs RD. 2022;22:257&#x2013;262. doi: 10.1007/s40268-022-00400-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40268-022-00400-8</ArticleId><ArticleId IdType="pmc">PMC9398904</ArticleId><ArticleId IdType="pubmed">35999352</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.-T., Zhang M.-W., Zhang Z.-Z., Cao Y.-D., Liu X.-Y., Miao R., Xu Y., Song X.-F., Song J.-W., Liu Y., et al. Abnormal Apelin-ACE2 and SGLT2 Signaling Contribute to Adverse Cardiorenal Injury in Patients with COVID-19. Int. J. Cardiol. 2021;336:123&#x2013;129. doi: 10.1016/j.ijcard.2021.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2021.05.029</ArticleId><ArticleId IdType="pmc">PMC8123373</ArticleId><ArticleId IdType="pubmed">34000358</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorrips S.N., Saucedo-Orozco H., S&#xe1;nchez-Aguilera P.I., De Boer R.A., Van der Meer P., Westenbrink B.D. Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure? Int. J. Mol. Sci. 2022;23:8631. doi: 10.3390/ijms23158631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23158631</ArticleId><ArticleId IdType="pmc">PMC9369142</ArticleId><ArticleId IdType="pubmed">35955784</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K. SGLT2 Inhibitors in People with and without T2DM. Nat. Rev. Endocrinol. 2021;17:75&#x2013;76. doi: 10.1038/s41574-020-00453-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00453-2</ArticleId><ArticleId IdType="pubmed">33293703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L.-M., Chen X.-H., Qiu M. Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. Front. Endocrinol. 2021;12:825100. doi: 10.3389/fendo.2021.825100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.825100</ArticleId><ArticleId IdType="pmc">PMC8785330</ArticleId><ArticleId IdType="pubmed">35082762</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie Chee Y., Dalan R. Repurposing Exercise Training and Pharmacological Therapies to Address the Post-Acute Sequelae of COVID-19 (PASC) in Diabetes Mellitus. Diabetes Res. Clin. Pract. 2023;199:110651. doi: 10.1016/j.diabres.2023.110651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2023.110651</ArticleId><ArticleId IdType="pmc">PMC10073874</ArticleId><ArticleId IdType="pubmed">37015258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra A., Chakraborty U., Ghosh S., Dasgupta S. Anticoagulation in COVID-19: Current Concepts and Controversies. Postgrad. Med. J. 2022;98:395&#x2013;402. doi: 10.1136/postgradmedj-2021-139923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-139923</ArticleId><ArticleId IdType="pubmed">33850011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper S.L., Boyle E., Jefferson S.R., Heslop C.R.A., Mohan P., Mohanraj G.G.J., Sidow H.A., Tan R.C.P., Hill S.J., Woolard J. Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. Int. J. Mol. Sci. 2021;22:8255. doi: 10.3390/ijms22158255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158255</ArticleId><ArticleId IdType="pmc">PMC8347967</ArticleId><ArticleId IdType="pubmed">34361021</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>